Avant Technologies Inc. (OTCQB:AVAI), through its joint venture with Ainnova Tech, is advancing Vision AI—a clinical screening platform now on the FDA’s radar and already in deployment across Latin America and Asia.
Issued on behalf of Avant Technologies Inc.
Imagine a world where diseases are flagged before symptoms even appear. Where AI reads medical images in seconds, spots hidden risks, and helps doctors deliver treatment tailored to the individual.
That world isn’t coming—it’s already here. AI in healthcare is scaling fast, with projections calling for growth from $26 billion to more than $600 billion by 2034.[1] By 2035, analysts believe AI could add another $461 billion in value[2] to a healthcare industry already on track to surpass $2.26 trillion.
Big names like Google and Microsoft are moving in, transforming diagnostics, patient monitoring, and health data systems. [3]
But for all the buzz, many tools remain fragmented, expensive, or too narrow for real clinical impact. [4]
That’s why the edge now belongs to focused innovators—those solving the hardest problems with scalable, real-world solutions. These are the platforms making early detection routine, expanding access in underserved regions, and laying the groundwork for what may become the most consequential transformation in modern medicine.[5],[6]
Enter Avant Technologies Inc. (OTCQB:AVAI), an emerging name in AI-driven healthcare, advancing the frontier of early disease detection through its Vision AI platform technology and its versatile retinal camera—already live in pilot programs and now moving toward its pre-submission meeting with the FDA in July for its planned clinical trial.
Backed by a joint venture with Ainnova Tech, Avant Technologies Inc. (OTCQB:AVAI) is building more than a diagnostic tool…
It’s developing a scalable, secure ecosystem—integrating clinical AI, advanced infrastructure, and embedded cybersecurity—designed to operate across diverse healthcare systems and regulatory environments.
This two-track strategy—real-world deployments in emerging markets paired with a U.S. regulatory pathway—offers both proof of concept and future access to one of the most lucrative markets in healthcare
By addressing the core challenges of early diagnosis, data integrity, and scalable implementation, Avant Technologies Inc. (OTCQB:AVAI) is helping shape a new category of applied AI—one grounded in clinical relevance, platform flexibility, and global reach.
Top 8 Reasons Why Avant Technologies Inc. (OTCQB:AVAI) Stands Out in the AI Healthcare Landscape:
- Positioned in a Multi-Billion Dollar Growth Megatrend
The healthcare AI market is growing at an estimated 30–38% CAGR, with projections ranging from $187.7 billion by 2030 to $613.8 billion by 2034. By 2035, AI could add $461 billion in value to a global healthcare system already projected to exceed $2.26 trillion. Avant is strategically positioned within this long-term transformation—one that touches diagnostics, imaging, chronic disease, and more.
- Real-World Deployments Already Underway
Unlike many early-stage AI companies still in the prototype phase, Avant’s Vision AI platform is already active in multiple countries across Latin America. These live deployments are generating clinical data, expanding access, and validating the platform in real healthcare settings. - Clear Regulatory Path with FDA Engagement in Motion
Avant and its partner Ainnova have submitted their pre-submission package to the FDA and secured a formal meeting date for July 2025. This milestone advances the company’s two-track strategy—deploy in fast-moving markets while building toward U.S. clearance under a 510(k) pathway. - Exclusive Licensing Rights Across Major Markets
Through its joint venture with Ainnova Tech, Avant holds global commercialization rights for Vision AI, including the U.S., Canada, and Europe. A recent expansion deal broadened its license scope just ahead of critical FDA - Institutional Validation from Apollo Hospitals Partnership
Avant’s partner Ainnova has aligned with Apollo Hospitals—Asia’s largest private hospital network. This collaboration adds both data-rich diagnostics (from over 2.3 million clinical cases) and strategic credibility across emerging healthcare ecosystems. - Two-Tiered Commercial Strategy: Global Pilots + U.S. Market Readiness
Avant’s strategy bridges near-term market access with long-term regulatory progress. It’s deploying Vision AI where approvals move quickly, while simultaneously building toward FDA clearance, giving the company both speed and scale in its rollout - Targeting a Critical Gap in Preventive Care
Vision AI addresses a growing global need: cost-effective, non-invasive early screening for conditions like diabetic retinopathy, cardiovascular disease, liver fibrosis, kidney disease, and type 2 diabetes. With over 1 billion people at risk for chronic conditions, tools like Vision AI could soon become essential across primary care and retail clinic settings. - Custom AI + Hardware Combo: Upgradable Retinal Camera System
Unlike many AI diagnostic platforms that rely on third-party hardware, Vision AI is being paired with a proprietary, low-cost retinal camera designed for seamless integration.[7] This exclusive system allows for automated image capture, rapid uploads, and dynamic algorithm upgrades, giving providers a flexible tool that evolves with emerging clinical needs and disease targets. The combined software and hardware offering supports a SaaS-style rollout across clinics, opticians, pharmacies, and workplace health providers.
The Big Picture in AI Healthcare
AI is rapidly reshaping healthcare from the inside out—especially in early detection, diagnostics, and clinical decision-making.
Barclays estimates the sector is growing at 30% annually[8], while Grand View Research forecasts it will hit $187.7 billion by 2030.[9]
By 2035, AI is expected to unlock $461 billion in added value[10] across a healthcare system already projected to surpass $2.26 trillion.
For companies focused on diagnostic accuracy and real-time screening, the tailwinds are even stronger.
Precedence Research sees the total healthcare AI market reaching $613.8 billion by 2034,[11] driven by demand for scalable, non-invasive tools that can support earlier intervention and cost-effective triage.
AI-powered imaging and diagnostics are a major growth driver—set to exceed $7.3 billion by 2032, according to current forecasts.[12] These tools are gaining traction in both high-tech hospitals and decentralized clinics alike, offering speed, accessibility, and the potential to relieve pressure on overburdened healthcare systems.
Avant Technologies Inc. (OTCQB:AVAI) is building for this reality—developing a platform that combines scalable screening, regulatory readiness, and global market access in one system designed to meet the moment.
Avant’s Strategic Position in Healthcare AI
Avant Technologies Inc. (OTCQB:AVAI) has emerged as one of the most strategically positioned small-cap players in the AI healthcare sector—combining global reach, regulatory momentum, and real-world deployment.
Through its joint venture with Ainnova Tech, Avant is advancing Vision AI, a non-invasive screening platform now operating in clinical pilot programs across Latin America[13] and India[14].
The system uses retinal scans and patient vitals to flag early signs of chronic conditions like diabetic retinopathy, cardiovascular disease, and liver or kidney disease—often before symptoms appear.
Unlike many early-stage AI ventures still in development, Avant has secured exclusive global licensing rights for Vision AI and has already filed its pre-submission package with the U.S. FDA. A formal meeting is scheduled for July 2025[15]—paving the way for potential market entry via the 510(k) pathway.
To strengthen its clinical footprint, Avant has also integrated four advanced diagnostic algorithms trained on more than 2.3 million patient cases through a strategic alliance with Apollo Hospitals, one of Asia’s largest healthcare providers.[16]
This two-pronged strategy—deploying in emerging markets while progressing through the U.S. regulatory pipeline—gives Avant a unique edge: it’s proving its technology in the field while building credibility with the world’s most influential regulators.
As AI transforms how healthcare is delivered, diagnosed, and scaled, Avant Technologies is carving out a distinct leadership lane—one grounded in practical tools, global accessibility, and long-term market relevance.
Leadership Built for Real-World Healthcare Impact
Avant Technologies Inc. (OTCQB:AVAI) together with its joint venture partner Ainnova Tech, is backed by a leadership team uniquely equipped to bring Vision AI to clinical scale. With experience across healthcare, AI, regulatory strategy, and operational execution, the team reflects a rare blend of technical innovation and go-to-market readiness.
Vinicio Vargas, CEO of Ainnova Tech, brings deep expertise in digital transformation and business development across healthcare systems in Latin America. His leadership has helped guide Vision AI from R&D to real-world deployment, while managing relationships with clinical partners, hospitals, and regulators.
Rodrigo Herrera, CTO of Ainnova Tech, is a seasoned AI architect and professor of computer science specializing in medical imaging. He leads the technical development of Vision AI’s diagnostic algorithms, including the integration of models trained on over 2.3 million patient cases.
Supporting the clinical roadmap is a world-class medical advisory team, including Dr. Lihteh Wu and Dr. Maziar Lalezary, both renowned retina specialists with affiliations to institutions like UCLA, Vanderbilt, Mount Sinai, and Cedars-Sinai. Their real-world insight helps ensure Vision AI meets clinical expectations while maintaining diagnostic precision.
On the advisory side, the team benefits from industry veterans like Ian K. Gordon, former COO of BlueCross BlueShield North Carolina, and Marcus Dantus, a serial tech entrepreneur and lead investor on Shark Tank Mexico.
This combined leadership bench gives Avant and Ainnova a strategic advantage—one built not only on technology, but on regulatory depth, clinical alignment, and global execution.
Ready to Follow the AI Healthcare Story That’s Already in Motion?
Avant Technologies Inc. (OTCQB:AVAI) is not waiting for the future to arrive—it’s building it now. With clinical deployments active, global licensing secured, and FDA engagement underway, the Vision AI platform is moving fast across emerging and regulated markets alike.
For those watching where AI is making the greatest near-term impact in healthcare, Avant represents a company already shifting from concept to execution.
If you’re tracking the evolution of AI in diagnostics, this is a name to keep on your radar.
Sign up now to receive company updates, news, and insights as Avant’s story continues to unfold.
Stay informed. Stay early. Stay connected.
USA News Group
Editorial Staff
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
SOURCES CITED:
[1] https://www.globenewswire.com/news-release/2024/08/12/2928598/0/en/Artificial-Intelligence-AI-in-Healthcare-Market-Size-Expected-to-Reach-USD-613-81-Bn-by-2034.html
[2] https://explodingtopics.com/blog/ai-statistics
[3] https://www.healthcaredive.com/news/ai-healthcare-google-microsoft-products-hlth-2024/731167/
[4] https://www.eetasia.com/the-transformative-impact-of-ai-on-digital-healthcare/
[5] https://www.bvp.com/atlas/roadmap-healthcare-ai
[6] https://www.analyticsinsight.net/artificial-intelligence/how-ai-changes-the-landscape-of-healthcare-systems
[7] https://ir.avanttechnologies.com/press-releases/2024/avant-technologies-and-ainnova-advancing-proprietary-retinal-camera-to-market-with-vision-ai-software
[8] https://www.investing.com/news/stock-market-news/ai-in-healthcare-barclays-sees-investment-promise-amid-regulatory-hurdles-3953117
[9] https://www.prnewswire.com/news-releases/ai-in-healthcare-market-size-to-reach-187-7-billion-by-2030-at-cagr-38-5—grand-view-research-inc-302439558.html
[10] https://explodingtopics.com/blog/ai-statistics
[11] https://www.globenewswire.com/news-release/2025/04/02/3054390/0/en/Artificial-Intelligence-AI-in-Healthcare-Market-Size-to-Hit-USD-613-81-Bn-by-2034.html
[12] https://www.globenewswire.com/news-release/2024/10/07/2958721/0/en/Artificial-Intelligence-in-Diagnostics-Market-to-hit-USD-7-3-billion-by-2032-says-Global-Market-Insights-Inc.html
[13] https://ir.avanttechnologies.com/press-releases/2025/avant-technologies-and-jv-partner-ainnova-accelerate-expansion-across-latin-america-following-key-role-at-healthcare-innovation-summit
[14] https://ir.avanttechnologies.com/press-releases/2025/avant-technologies-and-jv-partner-ainnova-strategically-align-with-apollo-hospitals-to-advance-ai-in-healthcare
[15] https://ir.avanttechnologies.com/press-releases/2025/avant-technologies-and-partner-ainnova-receive-fda-pre-submission-meeting-date-for-company-s-vision-ai-platform-technology
[16] https://ir.avanttechnologies.com/press-releases/2025/avant-technologies-and-jv-partner-ainnova-strategically-align-with-apollo-hospitals-to-advance-ai-in-healthcare
